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Abstract
Background: Chronic lung infection with the bacterium Pseudomonas aeruginosa is one of the hallmarks of cystic 
fibrosis (CF) and is associated with worsening lung function, increased hospitalisation and reduced life expectancy. A 
virulent clonal strain of P. aeruginosa (Australian epidemic strain I; AES-I) has been found to be widespread in CF 
patients in eastern Australia.
Methods: Suppression subtractive hybridization (SSH) was employed to identify genetic sequences that are present in 
the AES-I strain but absent from the sequenced reference strain PAO1. We used PCR to evaluate the distribution of 
several of the AES-I loci amongst a collection of 188 P. aeruginosa isolates which was comprised of 35 AES-I isolates (as 
determined by PFGE), 78 non-AES-I CF isolates including other epidemic CF strains as well as 69 P. aeruginosa isolates 
from other clinical and environmental sources.
Results: We have identified a unique AES-I genetic locus that is present in all 35 AES-I isolates tested and not present in 
any of the other 153 P. aeruginosa strains examined. We have used this unique AES-I locus to develop a diagnostic PCR 
and a real-time PCR assay to detect the presence of P. aeruginosa and AES-I in patient sputum samples.
Conclusions: We have developed diagnostic PCR assays that are 100% sensitive and 100% specific for the P. aeruginosa 
strain AES-I. We have also shown that Whatman FTA® Elute cards may be used with PCR-based assays to rapidly detect 
the presence of P. aeruginosa strains in CF sputum.
Background
The emergence of "epidemic" strains of P. aeruginosa in
cystic fibrosis (CF) clinics in Australia, the UK, Europe
and Canada has been reported [1-8]. In Australia, the
presence of a clonal isolate of P. aeruginosa was first
detected following the death of five unrelated children
attending the CF Clinic at the Royal Children's Hospital,
Melbourne [9,10]. Ensuing surveillance of the CF clinic in
1999 found that 55% of those infected with P. aeruginosa
had an identical or closely related strain to that of the five
young children [10]. This strain also appeared to show
increased virulence as it was associated with increased
hospitalisation and poorer pulmonary function amongst
infected patients [10,11]. We also reported a case of
cross-infection of a patient with non-CF bronchiectasis
that resulted in significant clinical deterioration [12]. This
strain has also been identified in CF clinics in Sydney and
Brisbane [1] and was previously referred to as m16 [10],
pulsotype I [1] or C3789 [13]. To avoid further confusion
we now refer to this strain as the Australian epidemic
strain-I (AES-I).
Two hospital environmental studies in 1995 and 1999
failed to identify a common source for AES-I, suggesting
person-to-person transmission or cross-infection [10].
To halt further dissemination of this strain, we elected to
institute strict cohort segregation measures whereby CF
children with AES-I infection were physically separated
from other CF children in the hospital wards and outpa-
tient clinics. Three years after the introduction of these
measures, we noted a significant decrease in the inci-
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vation strongly supports the notion that the AES-I is
transmitted by cross-infection between patients during
hospital and clinic visits and highlights the success of
cohorting strategies in limiting AES-I transmission.
AES-I strains isolated from CF patient sputa are cur-
rently identified via pulsed field gel electrophoresis
(PFGE). PFGE is an expensive, time consuming technique
requiring highly skilled personnel and thus cannot be
used as a means of routine surveillance for the presence
of the AES-I strain in patients attending CF clinics. There
is an urgent need for the development of a simple, rapid
diagnostic method that will enable routine surveillance
for AES-I in Australian CF clinics so that appropriate seg-
regation measures can be instituted in an expeditious
manner.
The development of diagnostic PCR-based assays have
proven to be effective tools for the rapid detection of
pathogens in infectious diseases, including other known
clonal P. aeruginosa strains [13,15-20]. Our aim in this
study was to determine if there were genetic sequences
that are unique to the AES-I that might be used to
develop a diagnostic PCR assay to enable rapid detection
of this strain directly from CF patient sputum.
Methods
Bacterial strains
Pseudomonas aeruginosa strains used in this study are
listed in Table 1. Eschericia coli strain DH5α was used for
transformation of the suppression subtractive hybridiza-
tion (SSH) library.
Molecular techniques
Chromosomal DNA for SSH was isolated using the Mas-
terpure DNA Purification Kit (Epicentre Technologies).
Chromosomal DNA used for PCR was isolated using
Masterpure DNA Purification Kit, DNeasy Tissue Purifi-
cation Kit (Qiagen Sciences) or Whatman FTA® Elute
cards. Miniprep DNA of SSH clones was prepared using
the QIAprep Spin Miniprep Kit (Qiagen Sciences).
Construction and screening of AES-I subtraction library
The AES-I isolate (strain 973) was used as the tester
strain for SSH. This strain was chosen from a collection
obtained from the Royal Children's Hospital, Melbourne
and had been previously identified as the clonal strain
AES-I [10]. The driver strain used for SSH was the
sequenced reference strain PAO1. The Clontech PCR-
Select Bacterial Genome Subtraction kit was used to gen-
erate the SSH library of RsaI fragments according to
manufacturer's instructions but with a hybridization tem-
perature of 73°C. The library of SSH PCR amplicons was
cloned in pGEM-T Easy (Promega). Individual clones
were miniprepped and sequenced. Nucleotide sequences
were determined by use of a PRISM Big Dye Terminator
Cycle Sequencing Ready Reaction kit (Applied Biosys-
tems) according to the manufacturer's instructions and
separated by capillary electrophoresis on an Applied Bio-
systems 3730S Genetic Analyser at the Monash Univer-
sity Micromon sequencing facility. Sequence data was
analysed using MacVector (Accelrys). To determine the
presence or absence of the SSH clone sequence in the
PAO1 genome, sequences were used in BLASTN
searches at the Pseudomonas genome project web-site
[21]. AES-I sequences were further analysed using
BLASTN and BLASTX searches [22] of the NCBI Gen-
bank databases http://www.ncbi.nlm.nih.gov.
PCR screening of strains
Oligonucleotides (Sigma Proligo) and annealing tempera-
tures used in the PCR assays are listed in Additional File
1. Primers to amplify AES-I genome sequences were
designed using MacVector (Accelrys). Primers to amplify
the conserved oprL gene have been described previously
[23]. Amplifications were carried out with an initial dena-
turation of 94°C for 2 min followed by 40 cycles consist-
Table 1: Pseudomonas aeruginosa strains used in this study
Strain type Number or identity Source PFGE typed prior 
to this study
Laboratory PAO1 (ATCC 15693), PAK, PA103, ATTC 27853
CF isolates 56 (sputum, bronchial lavage) Royal Children's Hospital, Melbourne Yes [10]
CF isolates 54 (sputum) Monash Medical Centre, Melbourne No
Non-CF isolates 7 (urine, sputum, bronchial lavage) Monash Medical Centre No
Non-CF isolates 52 Gribbles Pathology, Melbourne No
Environmental 6 Water Board Authority, Sydney No
Known clonal/epidemic Liverpool (LES431, LESB58), Manchester (8799, 
C3373), Midlands (8916, 10066), Stoke and Trent
Craig Winstanley (University of Liverpool, 
Liverpool, UK)
Yes [2,8,27]
Known clonal/epidemic Australian Epidemic Strain II (AES-II) Claire Wainwright (Royal Children's Hospital, 
Brisbane)
Yes [27]
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72°C (1 min) with an additional extension at 72°C for 10
min following completion of the 40 cycles. Reaction
products were electrophoresed on 2% (wt/vol) agarose
gels to determine the presence of the appropriately sized
amplicon.
Pulsed Field Gel Electrophoresis
Molecular typing by PFGE following digestion with SpeI
and DraI was performed as previously described [24]. An
isolate was considered to be AES-I or closely related to
AES-I if its PFGE patterns differed by no more than three
bands from the P. aeruginosa strain 973 [10].
PCR from sputum samples
Samples of sputum were swabbed onto Whatman FTA®
Elute cards and allowed to air dry. DNA from a 2 mm
diameter disc from each card was eluted into 50 μL of
water as per the manufacturer's instructions and added to
PCR tubes containing reaction mixtures for the PCR
amplification of either oprL or the SSH-identified AES-1
genomic locus HW2. P. aeruginosa strains were also iso-
lated from the sputum samples and typed by PFGE to val-
idate the PCR diagnosis.
Quantitative Real-time PCR
Primers and TaqMan® MGB probes (Applied Biosystems)
were designed from regions of the sequences of the HW2
locus and the oprL gene using the Primer Express® Soft-
ware v1.0 program (Applied Biosystems). Probe RTHW2-
P (Additional File 1) was labelled with fluorescent dye 6-
FAM at the 5' end and nonfluorescent quencher BHQ1 at
the 3' end (Sigma). Probe RToprL-P (Additional File 1)
was labelled with fluorescent dye 6-TAMRA at the 5' end
and nonfluorescent quencher BHQ2 at the 3' end
(Sigma). Real-time PCR mixtures contained, 0.8 μM con-
centrations of each primer, 0.6 μM concentration of the
probe, ABsoluteTM QPCR ROX (500 nM) Mix (ABgene)
and either 1 μl (genomic) or 5 μl (Whatman FTA® Elute
card) of template DNA. To monitor PCR inhibition the
TaqMan® Exogenous Internal Positive Control (IPC)
(Applied Biosystems) was multiplexed in the HW2 assay.
The oprL assay was performed as a singleplex reaction.
Amplification and detection were performed with the
Eppendorf Realplex Mastercycler using the following
program: 1 cycle of 95°C for 15 min and 40 cycles of 95°C
for 15 sec and 60°C for 1 min. Negative controls were
included in each assay. PCR products were also visualized
by agarose gel electrophoresis to verify product amplifi-
cation of the expected size. Cycle thresholds (Ct) from
experiments to determine method sensitivity were
reported as the average and standard deviation of three
biological repeats. Correlation coefficients between Ct
and DNA template concentration for each TaqMan assay
were calculated by regression analysis and amplification
efficiency was calculated using the formula: efficiency = -
1 + 10^(-1/slope). Primers and probes for quantitative





To identify genes unique to the AES-I genome, we per-
formed suppression subtractive hybridisation (SSH) of
DNA from AES-I isolate 973 against PAO1, the
sequenced reference strain of P. aeruginosa. We
sequenced 20 clones from the SSH clone library and iden-
tified 14 that contained AES-I sequences not present in
PAO1 (Additional File 2) and of these 3 (HW1, HW11
and HW20) encoded identical sequences. BLASTX anal-
ysis of the 12 unique AES-I SSH sequences indicated that
3 (HW15, HW16, HW21) were 100% identical to genes
located within the P. aeruginosa O6 antigen LPS biosyn-
thetic gene cluster [25] and thus identified AES-I as
belonging to the O6 serotype, a widespread serotype and
the same as the LES and Midlands epidemic strains [13].
Other homologies include a probable bacteriophage tail
protein (HW8), a very short mis-match repair protein
(HW6), a DNA cytosine methyltransferase (HW6), a
restriction endonuclease (HW12) and a dGTP triphos-
phohydrolase (HW22) (Additional File 2). Interestingly
loci HW1/11/20, HW18 and HW23 encode putative pro-
teins with 100% identity to 2 hypothetical proteins of the
sequenced Liverpool epidemic strain LESB58 (Additional
File 2). BLASTN and BLASTX searches with the remain-
ing 2 clones (HW2 and HW3) did not produce significant
hits in the Genbank sequence databases (Additional File
2).
Distribution of AES-I sequences in P. aeruginosa isolates
We designed PCR primer pairs to amplify each of the 9
different AES-I genetic sequences that were not found in
PAO1 and that did not localise to the O6 antigen gene
cluster. We first performed PCRs with each primer set
using the AES-I SSH driver strain (isolate 973) and PAO1
genomic DNA to confirm that the PCR reaction worked
and was specific to AES-I. One of the primers sets (HW1/
11/20) amplified a non-specific product in PAO1 and was
not used in further assays.
We next performed an initial PCR profiling with the
remaining 8 AES-I PCR primer sets on a collection of 9
AES-I strains (including driver strain), 9 non-AES-I CF
isolates, 7 non-CF clinical isolates, 6 environmental iso-
lates and the common laboratory strains PAO1, PA103,
PAK and ATCC 27853 (Table 2). Each of the CF isolates
in this collection had been previously genotyped by PFGE
and classified as AES-I or non-AES-I [10]. We also per-
formed PCR with primers that were designed to amplify
the conserved oprL gene that is present in all P. aerugi-
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was not due to failure of the PCR reaction. These PCR
assays showed that only the SSH loci HW2 and HW3
were unique to all 9 AES-I strains tested (Table 2).
The oprL, HW2 and HW3 PCR primer sets were then
used to screen a larger collection of P. aeruginosa strains
including a further 38 CF isolates that had been previ-
ously profiled by PFGE typing to be either AES-I (18) or
non-AES-I (20) [1,10], 9 representatives of the Liverpool,
Manchester, Midlands, Stoke, Trent and Australian pul-
sotype II epidemic strains [2,8,27] as well as another 52
non-CF clinical isolates (Table 3). These assays revealed
that the HW2 locus was present in all of the additional 18
AES-I isolates and none of the other P. aeruginosa strains
tested whereas HW3 was found to be present in all but 4
AES-I strains and none of the other P. aeruginosa strains
(Table 3). We also performed BLASTN analyses of the
genome sequences of the P. aeruginosa strains PA14, PA7,
PACS2, PA2192, and PAC3719 to determine the presence
of the HW2 and HW3 loci in these genomes and found
that neither locus is present in any of these sequenced
strains.
Detection of AES-I in P. aeruginosa isolates from a CF clinic
In 2005 we commenced a study to determine the preva-
lence of the AES-I strain in patients attending the
Monash Medical Centre CF clinic. Sputum was collected
by spontaneous expectoration or hypertonic saline induc-
tion from patients 6 years of age or older and plated onto
selective media to detect P. aeruginosa by standard tech-
niques [28]. PFGE was used to identify the genotype of 54
P. aeruginosa isolates of which 8 were identified to be
AES-I. PCR with the oprL, HW2 and HW3 primer sets
was performed on DNA purified from the same set of P.
aeruginosa isolates (Table 3). These PCR assays showed
that the HW2 and HW3 loci were absent in all 46 non-
AES-I P. aeruginosa isolates obtained in this study. Each
of the 8 AES-I strains possessed the HW2 locus whereas
the HW3 locus was present in 7 of the 8 AES-I isolates
(Table 3).
PCR detection of P. aeruginosa and AES-I in CF sputum 
using Whatman FTA® Elute cards
We explored the potential use of Whatman FTA® Elute
cards to purify DNA for use in PCR assays for the rapid
detection of P. aeruginosa strains directly from patient
sputum. A related technology, the FTA® card (Whatman),
has been shown to be an efficient method to store, trans-
port and isolate DNA from sputum samples suspected to
harbor Mycobacterium tuberculosis [29]. The FTA® Elute
technology has further simplified the elution of DNA for
PCR and is readily adaptable for routine pathology test-
ing. We used PCR assays for the oprL and HW2 loci to
determine if we could detect the presence of P. aeruginosa
and AES-I directly from sputum samples stored on
Whatman FTA® Elute cards. Sputum samples from
Monash Medical Centre CF clinic patients that were pos-
itive or negative for the AES-I strain as determined by
PFGE, were swabbed onto Whatman FTA® Elute cards,
DNA eluted and used in the oprL PCR assay to determine
the presence of P. aeruginosa in the sputum sample and in
a 2nd PCR assay with the HW2 AES-I primers to deter-
mine if the P. aeruginosa present in the sputum was AES-
Table 2: Distribution of AES-I genetic loci identified by suppression subtractive hybridisation in P. aeruginosa strains
Isolates oprL HW2 HW3 HW6 HW8 HW12 HW18 HW22 HW23
Initial screen
AES-I (n = 9) 9 9 9 9 9 9 9 9 9
non AES-I CF (n = 9) 9 0 0 1 0 0 0 1 2
non-CF clinical (n = 7) 7 0 0 1 1 1 5 0 2
Lab strains (n = 4)a 4 0 0 0 0 0 2 1 2
Environmental (n = 6) 6 0 0 0 1 0 2 0 0
a PAO1, PAK, PA103 and ATCC 27853
Table 3: Further screening of the distribution of AES-I 
genetic loci in P. aeruginosa strains
Isolates oprL HW2 HW3
Second screen
AES-I (n = 18) 18 18 14
non AES-I CF (n = 29)a 29 0 0
non-CF clinical (n = 52) 52 0 0
CF clinic screen
AES-I (n = 8) 8 8 7
non AES-I CF (n = 46) 46 0 0
a includes Liverpool, Manchester, Midlands, Trent, Stoke and AES-
II epidemic strains
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whilst both sputum samples were positive for the pres-
ence of P. aeruginosa as determined by the oprL PCR,
only the sputum from the patient harbouring AES-I was
positive with the HW2 PCR assay. These results demon-
strate the potential utility of using Whatman FTA® Elute
cards in PCR-based assays to rapidly determine the pres-
ence of P. aeruginosa and AES-I directly from sputum.
Development of a real-time PCR protocol to detect AES-I
To improve the diagnostic utility of the HW2 PCR we
then developed real-time PCR TaqMan assays for oprL
and the HW2 locus. Detection sensitivity of the HW2/
IPC multiplex and oprL TaqMan assays was assessed by
performing real-time PCR on dilutions of purified P.
aeruginosa genomic DNA from an AES-I strain. The
standard curves obtained with 10-fold serially diluted
genomic DNA preparations were linear over seven orders
of magnitude for HW2 and five orders for oprL (Table 4).
Based on the complete DNA sequence, the predicted
mass of a single copy of the P. aeruginosa PAO1 6,264,404
bp genome is 4.5 fg. Assuming a single copy of the target
in the P. aeruginosa AES-I genome, the HW2 assay
detected at least 2.2 × 102 genome copies. The oprL assay
was less sensitive, with a detection limit of 2.2 × 104
genomes. The HW2/IPC and oprL assays were also evalu-
ated as a triplex reaction but detection sensitivities were
reduced (data not shown).
Next, the specificity of the two TaqMan assays was
tested against purified DNA from P. aeruginosa PAO1, P.
putida and P. fluorescens. The HW2 TaqMan assay was
negative for these samples while oprL was positive for
both P. aeruginosa and P. putida. DNA was then extracted
from Whatman FTA® Elute cards spiked with AES-I posi-
tive and unique strains of P. aeruginosa. As predicted, all
extracts were oprL positive and only extracts from P.
aeruginosa AES-I strains were HW2 and oprL positive.
The same pattern of results was obtained with DNA
extracted from the AES-I positive and negative sputum
samples stored on Whatman FTA® Elute cards used in the
conventional PCR assay (Fig 1, Table 5). These data sug-
gest that the HW2 and oprL TaqMan assays may have suf-
ficient sensitivity and specificity for screening clinical
samples using sputum collected on Whatman FTA® Elute
cards.
Figure 1 PCR detection of oprL and the AES-I HW2 locus from CF 
sputum. Sputum from 2 patients that had been shown by PFGE 
screening to contain either AES-I or a unique strain of P. aeruginosa 
(UCF) was swabbed onto Whatman FTA® Elute cards. The oprL and HW2 
loci were amplified by PCR from these sputum samples (UCF-FTA, AES-
I-FTA) or chromosomal DNA (UCF-DNA, AES-I-DNA) purified from the 
P. aeruginosa strains isolated from the same sputum sample. These 
strains were also confirmed by PFGE to be AES-I or a unique strain of P. 




Table 4: Sensitivity of TaqMan PCR for detection of oprL and the AES-I HW2 locus
DNA per 
reaction (ng)
Genome equivalents/reationa oprL HW2
Average Ct TAMRAb,d Standard Deviation Average Ct FAMc,d Standard Deviation
1000 2.2 × 108 25.44 1.99 16.30 0.47
100 2.2 × 107 29.13 3.19 19.57 0.27
10 2.2 × 106 32.77 2.86 23.00 0.68
1 2.2 × 105 35.18 2.23 26.40 0.95
0.1 2.2 × 104 37.47 1.04 30.19 0.90
0.01 2.2 × 103 - - 33.23 0.84
0.001 2.2 × 102 - - 36.70 1.46
a based on weight of P. aeruginosa PAO1 genome of 4.5 fg
b oprL correlation coefficient r2 = 0.9865, amplification efficiency = 114.84%
c HW2 correlation coefficient r2 = 0.9996, amplification efficiency = 96.84%
d Fluorescent dye used for primer labeling; see Materials and Methods.
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AES-I is a highly transmissible virulent strain of P. aerugi-
nosa that has been identified in several CF clinics along
the eastern seaboard of Australia where surveillance pro-
grams have been introduced [1,10]. We have previously
shown that patient segregation has successfully limited
the spread of AES-I in a CF clinic in Melbourne [14].
There is currently an urgent need for a diagnostic tool
that will enable rapid identification of CF individuals that
harbour the AES-I strain so that appropriate segregation
measures can be employed during hospital and clinic vis-
its. Toward this end, we have used SSH and PCR to iden-
tify 2 genetic loci (HW2 and HW3) that are highly
conserved amongst AES-I isolates of P. aeruginosa. PCR
was utilised to profile the presence of these AES-I loci in
a total of 188 P. aeruginosa strains. These screens found
that the HW3 locus was absent in all 153 non-AES-I iso-
lates but present in only 30/35 of the AES-I strains (86%
sensitive and 100% specific) indicating that this locus is
present in a region of some variability between AES-I iso-
lates. The HW2 locus was found to be present in all 35
strains determined by PFGE to be AES-I and absent in all
153 non AES-I P. aeruginosa strains tested. These results
indicate that PCR for the HW2 locus is 100% specific and
100% sensitive for detection of the AES-I epidemic P.
aeruginosa strain.
The collection of strains used in this study included iso-
lates from CF individuals that were identified in our ini-
tial 1999 clinic surveillance to harbour the AES-I strain
[9,10] as well as isolates obtained over the subsequent 6
years from the same CF individuals. The HW2 locus was
present in all initial and subsequent AES-I isolates
obtained from the same individual indicating that this
locus did not display variability during chronic infection
over this time period.
The main purpose of the oprL PCR assay in our study
was to act as a positive control for DNA quality to avoid
false negative results in our PCR screens. Since we com-
menced our clinical surveillance study in 2005, it has
been shown that the ecfX locus is more specific than oprL
to identify P. aeruginosa from various environmental and
clinical extracts [30]. Accordingly, a PCR assay for the
ecfX locus could be substituted for the oprL assay to pro-
vide greater specificity for the presence of P. aeruginosa
in sputum samples if desired.
Compared with PFGE which can take 6 to 8 days to
obtain a diagnosis from time of receipt of patient sputum,
PCR-based assays have many benefits as potential diag-
nostic tools as they are simple, relatively inexpensive, do
not require highly skilled personnel, reduce handling and
detection errors and can significantly reduce the time
required to identify patients harbouring the AES-I strain.
We have shown that PCR amplification of the oprL and
HW2 loci can be used for the direct detection of P. aerug-
inosa and AES-I in CF sputum swabbed onto Whatman
FTA® Elute cards. We are now further assessing the
potential for these assays for use as routine surveillance
tools for P. aeruginosa and AES-I in CF sputum. The use
of Whatman FTA® Elute cards for sputum storage, trans-
port and DNA template purification for PCR is simple
and relatively inexpensive and could be easily adapted for
detection of other bacterial pathogens from a broad range
of respiratory and other infections.
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